Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

  • ID: 3846555
  • Report
  • 267 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • Boehringer Ingelheim GmbH
  • Exonate Limited
  • Icon Bioscience, Inc.
  • Ocular Therapeutix, Inc.
  • Pfizer Inc.
  • MORE
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

Summary

‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • Boehringer Ingelheim GmbH
  • Exonate Limited
  • Icon Bioscience, Inc.
  • Ocular Therapeutix, Inc.
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Wet (Neovascular / Exudative) Macular Degeneration Overview

Therapeutics Development

Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview

Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies

Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development

Aciont Inc.

Adverum Biotechnologies, Inc.

Allergan Plc

Alteogen Inc.

Amakem NV

Ampio Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Apexigen, Inc.

Applied Genetic Technologies Corporation

Benitec Biopharma Limited

Boehringer Ingelheim GmbH

Cell Medica Limited

Charlesson LLC.

Cipla Ltd.

Clanotech AB

Clearside BioMedical, Inc.

Clonz Biotech Private Limited

Coherus BioSciences, Inc.

Daiichi Sankyo Company, Limited

Diffusion Pharmaceuticals Inc.

Eleven Biotherapeutics Inc.

Exonate Limited

F. Hoffmann-La Roche Ltd.

Formycon AG

Graybug Vision Inc

GTx, Inc.

iCo Therapeutics Inc.

Icon Bioscience, Inc.

Iconic Therapeutics, Inc.

Kala Pharmaceuticals, Inc.

Kodiak Sciences Inc.

Mabion SA

MeiraGTx Limited

Mitotech S.A.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Ophthotech Corp.

Oxford BioMedica Plc

PanOptica, Inc.

Pfenex Inc.

Pfizer Inc.

pSivida Corp.

Regeneron Pharmaceuticals Inc

RegenxBio Inc.

RXi Pharmaceuticals Corporation

Santen Pharmaceutical Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

TRACON Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc.

Tyrogenex, Inc.

Xbrane Biopharma AB

Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(aflibercept + nesvacumab) - Drug Profile

(aflibercept + rinucumab) - Drug Profile

A-006 - Drug Profile

abicipar pegol - Drug Profile

AC-301 - Drug Profile

ACX-107 - Drug Profile

aflibercept - Drug Profile

aflibercept biosimilar - Drug Profile

aflibercept biosimilar - Drug Profile

AGN-151200 - Drug Profile

ALG-1001 - Drug Profile

AMA-0428 - Drug Profile

APL-2 - Drug Profile

APX-003 - Drug Profile

APX-3330 - Drug Profile

AVA-101 - Drug Profile

AVA-201 - Drug Profile

avacincaptad pegol sodium - Drug Profile

axitinib - Drug Profile

AXT-108 - Drug Profile

bertilimumab - Drug Profile

Beta-LGND2 - Drug Profile

BI-144807 - Drug Profile

brolucizumab - Drug Profile

C-16Y - Drug Profile

CBT-128 - Drug Profile

CLT-005 - Drug Profile

CLT-28643 - Drug Profile

cyclosporine - Drug Profile

DA-3131 - Drug Profile

danazol - Drug Profile

DE-120 - Drug Profile

DNX-214 - Drug Profile

Doxarubicin Pegylated - Drug Profile

Drug for Age Related Macular Degeneration - Drug Profile

DS-7080 - Drug Profile

ENV-1305 - Drug Profile

GB-101 - Drug Profile

Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile

Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile

hI-con1 - Drug Profile

IVMED-50 - Drug Profile

IVMED-55 - Drug Profile

K-106 - Drug Profile

KSI-201 - Drug Profile

LHA-510 - Drug Profile

Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile

OCU-200 - Drug Profile

OLX-301 - Drug Profile

ONL-1204 - Drug Profile

OPT-302 - Drug Profile

OXB-201 - Drug Profile

PAN-90806 - Drug Profile

pegpleranib sodium - Drug Profile

PF-05206388 - Drug Profile

PF-655 - Drug Profile

plastoquinone decyl triphenylphosphonium bromide - Drug Profile

Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile

ranibizumab - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

ranibizumab biosimilar - Drug Profile

Recombinant Protein for Age Related Macular Degeneration - Drug Profile

Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile

RES-529 - Drug Profile

RG-7716 - Drug Profile

RGX-314 - Drug Profile

RXI-109 - Drug Profile

SK-1011 - Drug Profile

Small Molecule for Wet AMD and Dry AMD - Drug Profile

Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile

Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile

SPHINX-31 - Drug Profile

squalamine lactate - Drug Profile

sunitinib malate - Drug Profile

Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile

TRC-105 - Drug Profile

triamcinolone acetonide - Drug Profile

TT-211 - Drug Profile

TT-231 - Drug Profile

X-82 - Drug Profile

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects

Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products

Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Development by Companies, H2 2016 (Contd..3)

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Development by Companies, H2 2016 (Contd..4)

Products under Development by Companies, H2 2016 (Contd..5)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Aciont Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Adverum Biotechnologies, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Allergan Plc, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Alteogen Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Amakem NV, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cell Medica Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charlesson LLC., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Cipla Ltd., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clonz Biotech Private Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Graybug Vision Inc, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Iconic Therapeutics, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by MeiraGTx Limited, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..3), H2 2016

Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H2 2016 255List of Figures

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aciont Inc.
  • Boehringer Ingelheim GmbH
  • Exonate Limited
  • Icon Bioscience, Inc.
  • Ocular Therapeutix, Inc.
  • Pfizer Inc.
  • MORE
Wet (Neovascular / Exudative) Macular Degeneration pipeline therapeutics constitutes close to 85 molecules. Out of which approximately 85 molecules are developed by Companies. Our latest report Wet (Neovascular Exudative) Macular Degeneration – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Wet (Neovascular / Exudative) Macular Degeneration Wet macular degeneration is a chronic eye disease that causes vision loss. Symptoms include visual distortions, decreased intensity or brightness of colors, well defined blurry spot or blind spot and abrupt onset. Predisposing factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 19, 7, 45 and 8 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aciont Inc.
Adverum Biotechnologies, Inc.
Allergan Plc
Alteogen Inc.
Amakem NV
Ampio Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
Apexigen, Inc.
Applied Genetic Technologies Corporation
Benitec Biopharma Limited
Boehringer Ingelheim GmbH
Cell Medica Limited
Charlesson LLC.
Cipla Ltd.
Clanotech AB
Clearside BioMedical, Inc.
Clonz Biotech Private Limited
Coherus BioSciences, Inc.
Daiichi Sankyo Company, Limited
Diffusion Pharmaceuticals Inc.
Eleven Biotherapeutics Inc.
Exonate Limited
F. Hoffmann-La Roche Ltd.
Formycon AG
Graybug Vision Inc
GTx, Inc.
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Iconic Therapeutics, Inc.
Kala Pharmaceuticals, Inc.
Kodiak Sciences Inc.
Mabion SA
MeiraGTx Limited
Mitotech S.A.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Ophthotech Corp.
Oxford BioMedica Plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
pSivida Corp.
Regeneron Pharmaceuticals Inc
RegenxBio Inc.
RXi Pharmaceuticals Corporation
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
TRACON Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc.
Tyrogenex, Inc.
Xbrane Biopharma AB
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll